Taken together, these data suggest that, similar to systemic inhibition of SHP2, targeted depletion of the SHP2 in pulmonary metastases leads to alterations of both the peripheral and tumor-infiltrating immune components. This evidence concerns the gene PTPN11 and neoplasm.